Nephrology III Panel

Editorial Board Liaison

Michelle M. Richardson, Pharm.D., FCCP, BCPS

Clinical Associate Professor

Northeastern University

Special and Scientific Staff

William B. Schwartz, M.D. Division of Nephrology

Tufts—New England Medical Center

Assistant Professor of Medicine

Tufts University School of Medicine

Boston, Massachusetts

Authors

Meredith J. Aull, Pharm.D.

Clinical Manager, Solid Organ Transplantation

Department of Pharmacy

New York Presbyterian Hospital – Weill Cornell Medical

Center

New York, New York

G. Mark Baillie, Pharm.D., MHA

Senior Research Scientist

CTI Clinical Trial and Consulting Services

Cincinnati, Ohio

Gilbert J. Burckart, Pharm.D., FCCP, FCP
Professor of Pharmacy
Co-Director, Pharmacogenomics/Immunogenetics
Laboratory
Department of Clinical Pharmacy
University of Southern California
Los Angeles, California

David I. Min, Pharm.D., MS, FCCP

Associate Professor

College of Pharmacy

Department of Pharmacy Practice and Administration

Western University of Health Sciences

Pomona, California

Nicole A. Weimert, Pharm.D., BCPS
Clinical Specialist, Solid Organ Transplant
Clinical Assistant Professor of Pharmacy
Medical University of South Carolina
Department of Pharmacy Services
Charleston, South Carolina

Reviewers

The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their careful review of the Book 2 chapters:

Mary C. Gurnee, Pharm.D. Pharmacist Consultant Overland Park, Kansas

Karen Norris, Pharm.D. Overland Park, KS

Long-Term Complications of Kidney Transplantation

Rita R. Alloway, Pharm.D., BCPS

Research Professor

Director, Transplant Clinical Research

University of Cincinnati

Cincinnati, Ohio

Todd P. Semla, Pharm.D., M.S., FCCP, BCPS, AGSF

Clinical Pharmacy Specialist

Benefits Management

U.S. Department of Veteran Affairs

Hines, Illinois

Associate Professor

Department of Psychiatry and Behavioral Sciences

The Feinberg School of Medicine

Northwestern University

Chicago, Illinois

Pharmacogenomics and Kidney Transplantation

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS

Clinical Pharmacist

Care Partners, Inc.

Morgantown, West Virginia

Robert E. Dupuis, Pharm.D., BCPS
Clinical Associate Professor of Pharmacy
School of Pharmacy
Division of Pharmacotherapy and Experimental
Therapeutics
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Nephrology III Panel

Management of Early Complications of Kidney Transplantation

Jennifer Trofe, Pharm.D., BCPS

Clinical Transplant Pharmacist

Department of Pharmacy Services

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

Eric T. Wittbrodt, Pharm.D., FCCP, FCCM, BCPS

Medical Education and Research Liaison

Medical Affairs, Research and Development

TAP Pharmaceutical Products Inc.

Lake Forest, Illinois

and

Associate Professor of Clinical Pharmacy (formerly)

Philadelphia College of Pharmacy

University of the Sciences in Philadelphia

Philadelphia, Pennsylvania

Disclosure of Potential Conflicts of Interest

Consultancies: Rita Alloway (Astellas Pharma Inc., Wyeth, Roche, Genzyme); Linda Awdishu (Dialysis Solutions, Inc.) Scott Bolesta (Blue Cross of Northeastern PA); Judy W.M. Cheng (Scios Pharmaceuticals, sanofi-aventis); Thomas Dowling (Gout and Uric Acid Education Society; Shire Laboratories, OBI); Teresa S. Dunsworth (Medicaid P&T Board; West Virginia University Hospitals P&T Committee); Robert Dupuis (Nabi Biopharmaceuticals, Astellas Pharma Inc.); Edward Foote (Kenyon & Kenyon, Scios Pharmaceuticals, ETHOS Health Communications, Roche); Joanna Hudson (Abbott Renal Care) Anne Hume (New England Research Institute, Pharmacotherapy Consultants of New England); Linda G. Martin (Albany County Family Planning, Wyoming Medicaid Drug Utilization, Downtown Clinic – Laramie, WY, Wyoming Society of Health-System Pharmacy); Gary Matzke (American College of Clinical Pharmacology, ASHP, AACP); Michelle M. Richardson (National Kidney Foundation, Agency for Health Care Research/Centers for Medicare and Medicaid Services, Amgen); Jennifer Trofe (Lexi-Comp); Lori Wazny (Ortho-Biotech); Nicole Weimert (ACCP); Eric T. Wittbrodt (GSK/Adolor).

Stock Ownership: G. mark Baillie (Pfizer); Katherine H. Chessman (Proctor and Gamble, stock owned by spouse or significant other); Gary Matzke (ICOS); Michelle M. Richardson (TEI Biosciences Inc., stock owned by spouse or significant other). **Royalties:** Gilbert Burckart (University of Pittsburgh); Gary Matzke (McGraw-Hill).

Grants: Rita Alloway (Bristol Myers Squibb, Novartis, Isotechnika, Y's Therapeutics, Idun Pharmaceuticals, Fujisawa Healthcare Incorporated, Astellas Pharma Inc., SangStat Medical Corporation, Wyeth Ayerst, NIH, Roche, Novartis, Genzyme); Linda Awdishu (Roche); Gilbert Burckart (NIH); Thomas Dowling (NovaCardia, NIH, ACCP); Edward Foote (Genzyme); Joanna Hudson (ACCP, Watson Pharmaceuticals); Anne Hume (National Library of Medicine, Bureau of Health Professions, Agency for Healthcare Research and Quality); Lisa Hutchison (Pfizer, Ortho-Biotech, Beverly Enterprises); Linda G. Martin (State of Wyoming Department of Health Aging Division); Bruce Mueller (Cubist, Merck); Kari Olson (ACCP, Heart and Stroke Foundation of Canada, Kaiser Permanente of Colorado); Michelle M. Richardson (QualityMetric and Tufts-New England Medical Center); Jennifer Trofe (Dialysis Clinic International); Eric T. Wittbrodt (Ortho-Biotech, Centocor).

Honoraria: Rita Alloway (Astellas Pharma Inc., Roche, Wyeth Ayerst); Linda Awdishu (American Regent); Judy W.M. Cheng (Scios Pharmaceuticals, Millennium Pharmaceuticals); Katherine H. Chessman (Pfizer); Thomas Dowling (Abbott Labs); Edward Foote (American Regent, Amgen); Joanna Hudson (Abbott Renal Care, Watson Pharmaceuticals); Bruce Mueller (Amgen); Michelle M. Richardson (Amgen); Lori Wazny (Roche); Eric T. Wittbrodt (GSK/Adolor, Amgen, Ortho-Biotech, LP). Other: Todd P. Semla (spouse or significant other employed by Abbott); Eric T. Wittbrodt (Tap Pharmaceuticals).